

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number
WO 2004/100897 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2004/014827
- (22) International Filing Date: 12 May 2004 (12.05.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/469,737 12 May 2003 (12.05.2003) US
- (74) Agent: KENT, Cheng, H.; Cohen, Pontani, Lieberman & Pavane, 551 Fifth Avenue, Suite 1210, New York NY 10176 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: SCINOPHARM TAIWAN, LTD.; 1, Nan-ke 8th Road, Tainan Science-Based Industrial Park, Tainan County 741 (TW).
- (71) Applicant (*for LC only*): SCINOPHARM TAIWAN, LTD. [US/US]; P.O. Box 53130, San Jose, CA 95153 (US).
- (72) Inventors: LIN, Chien-Hsing; 12F-3, No. 1, Lane 216, Jen-I Road, Lin-Ko Shuang, Taipei County 244 (TW). CHENG, Yung-Fa; 16, Wei-Du Tou, Chia Li, Tainan County 726 (TW). CHENG, Kau-Ming; 8F-1, No 119, Rong-Yu Street, Tainan City (TW).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF 7-ALKYL-10-HYDROXY-20(S)-CAMPTOTHECIN

(57) Abstract: The key intermediate in any synthesis of Irinotecan is 7-ethyl-10-hydroxy-20(S) camptothecin. A process for the efficient synthesis of this intermediate is demonstrated proceeding through readily available 20(S)-camptothecin. Various other tecan compounds may be made by use of corresponding 7-alkyl-10-hydroxy-20(S)-camptothecin intermediates.



Process for the Preparation of 7-Alkyl-10-Hydroxy-20(S)-
Camptothecin

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

This invention relates to an efficient three-step process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin from the readily available natural product, 20(S)-camptothecin. The invention also demonstrates a
10 novel intermediate useful in this synthesis.

2. Description of the Related Art

Camptothecin derivatives have shown significant cytotoxic activity and several have been developed into
15 useful pharmaceuticals. Specifically Irinotecan (Campto) has shown excellent activity toward colon-rectal cancers and is widely marketed. It shows considerable advantage over other camptothecin derivatives in that it is water soluble.

20 Irinotecan is prepared in several steps from the key intermediate, 7-ethyl-10-hydroxy-20(S)-camptothecin. Considerable effort has been expended to introduce both the 10-hydroxy and the 7-ethyl functionality into the camptothecin molecule. Therefore, while there is some
25 prior art associated with each of these individual groups, there is very little knowledge on introduction of both these functionality simultaneously into the molecule.

Sawada (Chem. Pharma. Bull., 39(12), 3183(1991))
30 demonstrates the synthesis of 7-ethyl-10-hydroxy-20(S)-camptothecin through the synthesis of 7-ethyl-20(S)-camptothecin by known means, the subsequent formation of an N-oxide and the photochemical rearrangement to

provide 7-ethyl-10-hydroxy-20(S)-camptothecin. However, this synthesis suffers considerably from the insolubility of 7-ethyl-20(S)-camptothecin in suitable solvents and thus only small quantities can be prepared.

5 10-Hydroxy-20(S)-camptothecin has been prepared by the hydrogenation of 20(S)-camptothecin to 1,2,6,7-tetrahydro-20(S)-camptothecin and subsequent oxidation. Thus US Pat. 5,734,056 describes the preparation through the hydrogenation of 20(S)-camptothecin to 1,2,6,7-
10 tetrahydro-20(S)-camptothecin followed by the oxidation with iodosobenzene derivatives specifically esters such as iodobenzenediacetate. Japanese pat. No. 59-5188 discloses the hydrogenation of camptothecin followed by oxidation with agents such as CAN(cerium (IV) ammonium
15 nitrate, chromic acid, potassium permanganate, Fremy's salt. Similarly, Sawada, et. al. (Chem.Pharm. Bull. 39(120)3183, 1991) describes a reduction and oxidation with lead tetraacetate. In all these cases, the use of a 7-substituted derivative has not been demonstrated.


20 The preparation of 7-ethyl-20(S)-camptothecin has been demonstrated previously through the Fenton reaction by employing 20(S)-camptothecin and propionaldehyde with ferrous sulfate and sulfuric acid.

Therefore there is a need for an efficient
25 synthesis of 7-ethyl-10-hydroxy-20(S)-camptothecin which can be used in commercial scale.

SUMMARY OF THE INVENTION

The present invention provides as one
30 embodiment a novel process employing the formation of the 7-ethyl-20(S)-camptothecin followed by the catalytic reduction and subsequent oxidation to the desired 7-

ethyl-10-hydroxy-20(S)-camptothecin, shown in Scheme I, which is useful in the synthesis of Irinotecan.



5

DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

The formation of 7-alkyl-20(S)-camptothecin (I) was accomplished by known methodology. It is known in the literature that the hydrogenation of tetra-substituted olefins is very difficult. Therefore, it was expected that the hydrogenation of this compound to 7-alkyl-1,2,6,7 - tetrahydro-20(S)-camptothecin (II) would be challenging. We were surprised to learn that we could indeed accomplish this hydrogenation in good yield and good purity using PtO_2 as the catalyst in a suitable solvent in which the 7-alkyl-20(S)-camptothecin is soluble. Catalysts other than PtO_2 may be used, such as reduction catalyst containing at least one of the elements platinum, rhodium, lawrencium, and ruthenium. Further, the hydrogenation step may be conducted with a

catalysis modifier, such as dimethylsulfoxide and ammonium hydroxide. Acetic acid is a preferred solvent for this purpose. Other solvent systems such as alcohols and mixtures of acetic acid and alcohols can be employed
5 in this hydrogenation but high solubility of camptothecin in acetic acid makes acetic acid the most desirable solvent. By employing this catalytic hydrogenation, the desired product can be easily obtained in greater than 90% yield.

10 It was found that unlike the known 1,2,6,7-tetrahydro-20(S)-camptothecin, 7-alkyl-1,2,6,7-tetrahydro-20(S)-camptothecin (II) is oxidized readily back to 7-alkyl-20(S)-camptothecin (I) under an oxygen atmosphere. Therefore there was a question as to whether
15 the oxidation would produce the 10-hydroxy derivative in good yield. In fact, the oxidation with iodobenzenediacetate in acetic acid/water did produce the desired 7-alkyl-10-hydroxy-20(S)-camptothecin (III) in very good yield. The reaction can be carried out in a
20 variety of solvent systems but again acetic acid/water was the most convenient and preferred solvent system. Other suitable solvents include C₁-C₆ ester, C₁-C₆ acid, C₁-C₆ alcohol and water. More specifically, the C₁-C₆ acid may be butenic acid, propanoic acid and acetic
25 acid. The reaction may also be carried out with various other oxidizing agents, including those containing hypervalent iodine, ruthenium (VIII), manganate (VII), osmium (VIII), lead (IV) and chromium (VI). The product precipitates during the reaction and can be collected by
30 filtration. The product obtained is of sufficient purity to be used directly or it can be purified by

recrystallization from organic solvents such as acetic acid.

Therefore the present invention provides for an efficient synthesis of 7-alkyl-10-hydroxy-20(S)-
5 camptothecin (III).

Examples

Preparation of 7-ethyl-20(S)-camptothecin (I)

20(S)-camptothecin (60.0 g), ferrous sulfate
10 heptahydrate (12.0 g) and 9N sulfuric acid (1200 ml) are subsequently charged to a 5-L reactor equipped with a mechanical stirrer, condenser and a thermometer under nitrogen atmosphere. The resulting mixture is stirred at 25 °C until all the suspension is dissolved, and it is
15 cooled to between -10 and 0 °C. Propionyl aldehyde (10.0 g) is added to the cold reaction mixture. A solution of 10% hydrogen peroxide (116.9 g) and propionyl aldehyde (15.0 g) are simultaneously charged to the cold reaction mixture over a period of 30-60 minutes, while
20 maintaining the temperature at 10 to 0 °C. The resulting mixture is stirred at the same temperature for 60 to 90 minutes. The reaction mixture was diluted with water and neutralized with aqueous ammonium hydroxide to precipitate out the desired product. The crude product
25 was crystallized from acetic acid and water to give compound I, 49.83 g in 71.6% yield with purity of 95.16% by HPLC. ¹H-NMR (DMSO-d₆) δ: 0.9 (3H, t), 1.3 (3H, t), 1.85 (2H, q), 3.2 (2H, q), 5.28 (2H, s), 5.44 (2H, s), 6.5 (1H, s), 7.32 (1H, s), 7.7 (1H, dd), 7.85 (1H, dd),
30 8.15 (1H, d), 8.26 (1H, d).

Preparation of 7-ethyl-1,2,6,7-tetrahydro-20(S)-camptothecin (II)

7-ethyl-20(S)-camptothecin (I) (30.0 g) and acetic acid (900 ml) were charged together and heated to 80 °C to facilitate the dissolution. The resulting solution is then transferred to a 2-L autoclave reactor and cooled to room temperature. Ammonium hydroxide (30% contents, 3.4 ml), platinum oxide and dimethyl sulfoxide (2.2 ml) were added into the resulting suspension at 25 °C. The resulting mixture is then subjected to hydrogenation at a hydrogen pressure of 5 bars until the starting material, 7-ethyl-20(S)-camptothecin I, disappeared by TLC analysis. The catalyst was removed by filtering through a pad of celite and washed with acetic acid, the resulting solution is used directly for the next reaction. The sample was characterized by HPLC, NMR, IR and LC/MS analysis. HPLC shows three diastereoisomers in a ratio of 6: 61: 13, which are detected by LC/MS to have MS m/z: 380 (M^+). 1H -NMR ($DMSO-d_6$) δ : 0.78 (3H, t), 0.82 (3H, m), 1.2-1.35 (2H, m), 1.8 (3H, m), 2.65 (1H, m), 3.12 (1H, m), 3.75 (1H, dd), 4.08 (1H, dd), 4.92 (1H, dd), 5.23 (1H, s), 6.48 (1H, s), 6.5-6.98 (4H, m), 6.62 (1H, s); IR (KBr) ν : 3310, 2967, 1744, 1652, 1586, 1491, 1465 cm^{-1} .

25

Preparation of 7-ethyl-10-hydroxy-20(S)-camptothecin (III)

The hydrogenated filtrate of 7-ethyl-1,2,6,7-tetrahydro-20(S)-camptothecin was charged to a 3-L, four-necked round bottom flask equipped with a mechanical stirrer, thermometer under nitrogen atmosphere, and was cooled to 10° C. Water (900 ml) was

30

added to the solution and the resulting solution was stirred at this temperature for 20 minutes. Subsequently, iodobenzene diacetate (65.5 g) was added to the solution in several small portions, while
5 maintaining the temperature below 10° C. The resulting mixture was stirred at this temperature until the complete disappearance of the starting material, 7-ethyl-1,2,6,7-tetrahydro-20(S)-camptothecin (II), as monitored by TLC. The reaction was quenched by the
10 addition of Methanol (230 ml) to facilitate the precipitation of the product. The reaction slurry was then filtered and the collected solids are washed with aqueous acetic acid and methanol to give the desired product 28.3 g (90% overall yield in two steps) . 1H-NMR
15 (DMSO-d₆) δ: 0.9 (3H, t), 1.32 (3H, t), 1.88 (2H, q), 3.1 (2H, q), 5.28 (1H, s), 5.42 (1H, s), 6.46 (1H, s), 7.28 (1H, s), 7.4 (2H, m), 8.0 (1H, d), 10.5 (1H, s).

Preparation of 7-methyl-20(S)-camptothecin

20 We performed a process corresponding to the above process to make 7-ethyl-20(S)-camptothecin to provide the product, 25.6 g in 60% yield. 1H-NMR (DMSO-d₆) δ: 0.90 (3H, t), 1.88 (2H, m), 2.79 (3H, s), 5.29 (2H, s), 5.44 (2H, s), 6.51 (1H, s), 7.34 (1H, s), 7.73 (1H, t),
25 7.86 (1H, t), 8.15 (1H, d), 8.25 (1H, d).

Preparation of 7-methyl-1,2,6,7-tetrahydro-20(S)-camptothecin

We performed a process corresponding to the above process to make 7-ethyl-1,2,6,7-tetrahydro-20(S)-
30 camptothecin. HPLC of the product shows three diastereoisomers in a ratio of 13: 68: 19, 1H-NMR (DMSO-

d₆) δ : 0.78 (3H, t), 1.02 (3H, d), 1.72 (2H, m), 1.90 (3H, m), 3.01 (1H, m), 3.17 (1H, m), 3.91 (1H, m), 4.06 (1H, m), 4.91 (1H, m), 5.21 (1H, s), 6.30 (1H, s), 6.56-6.6 (2H, m), 6.8-7.0 (2H, m).

5 Preparation of 7-methyl-10-hydroxy-20(s)-camptothecin

We performed a process corresponding to the above process to make 7-ethyl-10-hydroxy-20(s)-camptothecin (III). The HPLC of the reaction product shows 17% of the desired product and 41% 7-methyl-20(S)-camptothecin.

10 References that are cited herein are incorporated by reference in their entirety.


Thus, while there have shown and described and pointed out fundamental novel features of the invention as applied to a preferred embodiment thereof, it will be understood that various omissions and substitutions and changes in the form and details of the process illustrated, and in its operation, may be made by those skilled in the art without departing from the spirit of the invention. For example, it is expressly intended that all combinations of those elements and/or method steps which perform substantially the same function in substantially the same way to achieve the same results are within the scope of the invention. Moreover, it should be recognized that structures and/or elements and/or method steps shown and/or described in connection with any disclosed form or embodiment of the invention may be incorporated in any other disclosed or described or suggested form or embodiment as a general matter of design choice. It is the intention, therefore, to be limited only as indicated by the scope of the claims appended hereto.

15
20
25
30

CLAIMS


We claim:

1. A compound of the formula:



5

2. A process for the preparation of 7-ethyl-10-hydroxy-20(S)-camptothecin of formula:



10

comprising the steps of:

reducing 7-ethyl-20(S)-camptothecin to 7-ethyl-1,2,6,7-tetrahydro-20(S)-camptothecin with hydrogen gas catalyzed by a reduction catalyst; and

15

oxidizing the 7-ethyl-1,2,6,7-tetrahydro-20(S)-camptothecin with an oxidizing agent to produce 7-ethyl-10-hydroxy-20(S)-camptothecin.

3. The process of claim 2, wherein the oxidizing agent is selected from the group consisting of hypervalent iodine, ruthenium (VIII), manganate (VII), osmium (VIII), lead (IV) and chromium (VI).
- 20

4. The process of claim 2, wherein the oxidizing agent is iodobenzenediacetate.

5. The process of claim 2, wherein the oxidizing step is performed in a solvent system.

5 6. The process of claim 2 wherein the organic solvent is selected from the group consisting of C₁-C₆ ester, C₁-C₆ acid, C₁-C₆ alcohol and water.

7. The process of claim 6 wherein the C₁-C₆ acid is selected from the group consisting of butenic acid, 10 propanoic acid, and acetic acid.

8. The process of claim 6 wherein the C₁-C₆ acid is acetic acid.

9. The process of claim 2, wherein the reduction catalyst comprises the element selected from the group 15 consisting of platinum, rhodium, lawrencium, and ruthenium.

10. The process of claim 2, wherein the reducing step is performed in the presence of a catalysis modifier.

20 11. The process of claim 10 wherein the catalyst modifier is dimethylsulfoxide.

12. The process of claim 10 wherein the catalyst modifier is ammonium hydroxide.


13. A process of producing irinotecan comprising:
25 reducing 7-ethyl-20(S)-camptothecin to 7-ethyl-1,2,6,7-tetrahydro-20(S)-camptothecin with hydrogen gas catalyzed by a reduction catalyst;

oxidizing the 7-ethyl-1,2,6,7-tetrahydro-20(S)-camptothecin with an oxidizing agent to produce 7-ethyl-10-hydroxy-20(S)-camptothecin; and
30

using 7-ethyl-10-hydroxy-20(S)-camptothecin as an intermediate to prepare the irinotecan product.

11

14. A compound of the formula:




5

wherein R is a lower alkyl group having 1 to 6 carbon atoms.

15. A process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin of the formula

10



wherein R is an alkyl group, comprising the steps of:

reducing 7-alkyl-20(S)-camptothecin to 7-alkyl-1,2,6,7-tetrahydro-20(S)-camptothecin with hydrogen gas catalyzed by a reduction catalyst; and

oxidizing the 7-alkyl-1,2,6,7-tetrahydro-20(s)-camptothecin with an oxidizing agent to produce 7-alkyl-10-hydroxy-20(S)-camptothecin

16. A process for producing tecans comprising the process according to claim 15.